|
New Guidance to Diagnose and Treat Tumor-induced Osteomalacia (TIO)
This 30-minute CME-accredited program, hosted by Aliya Khan, MD, Clinical Professor of Medicine at McMaster University, highlights the best practices to diagnose and treat tumor induced osteomalacia (TIO) based on the recently published global guidance document in the Journal of Internal Medicine.
This activity has been designed to meet the educational needs of physicians specializing in neurology, orthopedics, internal medicine/general practice, rheumatology, endocrinology, pain management... |
|
|
Ace the Case: Pulmonary Arterial Hypertension (PAH) Presentation and Evaluation by Pulmonary Specialist
Pulmonary hypertension (PH) comprises a heterogeneous group of disorders that share a common clinical feature - mean pulmonary artery pressure greater than 20 mm Hg. PH may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Early diagnosis is critical to ensure patients are eligible for the widest spectrum of treatment options and that treatment is initiated as early as possible in the disease process. PH is classified into 5 c... |
|
|
Ace the Case: Pulmonary Arterial Hypertension (PAH) Treatment Decisions and Therapy Initiation by Pulmonary Hypertension Specialist
Pulmonary hypertension (PH) comprises a heterogeneous group of disorders that share a common clinical feature - mean pulmonary artery pressure greater than 20 mm Hg. PH may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. Early diagnosis is critical to ensure patients are eligible for the widest spectrum of treatment options and that treatment is initiated as early as possible in the disease process. PH is classified into 5 c... |
|
|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |
|